Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | THRA | P10827 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17133994 | 0.88 | SLC6A2 (0.33) | SLC6A2TAAR1LMNACYP2D6 | |
| SCHEMBL1067474 | 0.83 | SLC6A2 (0.33) | SLC6A2TAAR1LMNACYP2D6 | |
| SCHEMBL14814630 | 0.79 | — | — | |
| SCHEMBL12981412 | 0.79 | ESR1 (0.31) | ESR1SLC6A2TAAR1 | |
| SCHEMBL1072823 | 0.79 | ALDH1A1 (0.32) | SLC6A2TAAR1 | |
| SCHEMBL533194 | 0.78 | — | — | |
| SCHEMBL533106 | 0.78 | — | — | |
| SCHEMBL27439864 | 0.77 | SMN1; SMN2 (0.38) | SLC6A2TAAR1LMNA | |
| SCHEMBL28668954 | 0.76 | — | — | |
| SCHEMBL5696355 | 0.75 | ATM (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270367-A1 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | claimed |
| US-20090042961-A1 | OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. | 2009-02-12 | — | — | US | claimed |
| US-7385085-B2 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2008-06-10 | — | — | US | claimed |
| US-20070149584-A9 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | JOHN VARGHESE | 2007-06-28 | — | — | US | claimed |
| EP-1773758-A1 | OXIME DERIVATIVE HYDROXYETHYLAMINE ASPARTYL-PROTEASE INHIBITORS | Elan Pharmaceuticals, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| EP-1773756-A2 | OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | Elan Pharmaceuticals, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| EP-1735293-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-12-27 | — | — | EP | claimed |
| EP-1730125-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-12-13 | — | — | EP | claimed |
| EP-1729755-A1 | METHODS OF TREATMENT OF AMYLOIDOSIS USING ASPARTYL-PROTEASE INIHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-12-13 | — | — | EP | claimed |
| US-20060135581-A1 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-06-22 | — | — | US | claimed |
| US-20060128715-A1 | Oxime derivative hydroxyethylamine aspartyl-protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | claimed |
| WO-2006010094-A1 | OXIME DERIVATIVE HYDROXYETHYLAMINE ASPARTYL-PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-01-26 | — | — | WO | claimed |
| WO-2006010095-A2 | OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS INC. (US) | 2006-01-26 | — | — | WO | claimed |
| US-20060014790-A1 | Methods of treatment of amyloidosis using spirocyclohexane aspartyl-protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-01-19 | — | — | US | claimed |
| US-20050239790-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | claimed |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | claimed |
| WO-2005087751-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | claimed |
| WO-2005087752-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | claimed |
| WO-2005070407-A1 | METHODS OF TREATMENT OF AMYLOIDOSIS USING ASPARTYL-PROTEASE INIHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-08-04 | — | — | WO | claimed |
| WO-2024099911-A1 | IRON CARBONYL COMPLEXES WITH CHIRAL, BIDENTATE BIPHOSPHINE LIGANDS | BASF SE (DE) | 2024-05-16 | — | — | WO | disclosed |
| WO-2023137133-A2 | PROCESS FOR THE SELECTIVE CATALYTIC HYDROGENATION OF DIENONES | BASF SE (DE) | 2023-07-20 | — | — | WO | disclosed |
| US-RE49036-E1 | Method for synthesizing optically active carbonyl compounds | BASF SE (DE) | 2022-04-19 | — | — | US | disclosed |
| EP-3489213-B1 | COMPOSITION FOR USE IN A METHOD FOR THE PREPARATION OF OPTICALLY ACTIVE CARBONYL COMPOUNDS | BASF SE (DE) | 2021-04-28 | — | — | EP | disclosed |
| EP-3489213-A1 | COMPOSITION FOR USE IN A METHOD FOR THE PREPARATION OF OPTICALLY ACTIVE CARBONYL COMPOUNDS | BASF SE (DE) | 2019-05-29 | — | — | EP | disclosed |
| US-10301244-B2 | Method for synthesizing optically active carbonyl compounds | BASF SE (DE) | 2019-05-28 | — | — | US | disclosed |
| CN-105647274-B | Compound, ink, print cartridge and ink jet recording method | 佳能株式会社 | 2019-04-26 | — | — | CN | disclosed |
| EP-3233778-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CARBONYL COMPOUNDS | BASF SE (DE) | 2019-02-20 | — | — | EP | disclosed |
| WO-2019025153-A1 | USE OF SUBSTITUTED N-SULFONYL-N'-ARYL DIAMINOALKANES AND N-SULFONYL-N'-HETEROARYL DIAMINOALKANES OR SALTS THEREOF FOR INCREASING THE STRESS TOLERANCE IN PLANTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2019-02-07 | — | — | WO | disclosed |
| US-20180244598-A1 | METHOD FOR SYNTHESIZING OPTICALLY ACTIVE CARBONYL COMPOUNDS | BASF SE (DE) | 2018-08-30 | — | — | US | disclosed |
| US-20180199575-A1 | SUBSTITUTED OXOTETRAHYDROQUINOLINYLPHOSPHINIC ACID AND PHOSPHINIC ACID AMIDES OR SALTS THEREOF AND USE THEREOF TO INCREASE STRESS TOLERANCE IN PLANTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-07-19 | — | — | US | disclosed |
| EP-3322296-A1 | SUBSTITUTED OXO-TETRAHYDROQUINOLINYL-PHOSPHINIC ACID AND PHOSPHINIC ACID AMIDES OR SALTS THEREOF AND USE THEREOF TO INCREASE STRESS TOLERANCE IN PLANTS | Bayer CropScience Aktiengesellschaft (DE) | 2018-05-23 | — | — | EP | disclosed |
| US-9975837-B2 | Method for synthesizing optically active carbonyl compounds | BASF SE (DE) | 2018-05-22 | — | — | US | disclosed |
| US-20180057437-A1 | METHOD FOR SYNTHESIZING OPTICALLY ACTIVE CARBONYL COMPOUNDS | BASF SE (DE) | 2018-03-01 | — | — | US | disclosed |
| US-20180020662-A1 | Substituted 1-cycloalkyl-2-oxotetrahydroquinolin-6-ylsulfonamides or salts thereof and use thereof to increase stress tolerance in plants | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-01-25 | — | — | US | disclosed |
| EP-3256448-A1 | SUBSTITUTED 1-CYCLOALKYL-2-OXOTETRAHYDROQUINOLIN-6-YL-SULFONAMIDES OR SALTS THEREOF AND USE THEREOF TO INCREASE STRESS TOLERANCE IN PLANTS | Bayer CropScience Aktiengesellschaft (DE) | 2017-12-20 | — | — | EP | disclosed |
| EP-3233778-A1 | METHOD FOR SYNTHESIZING OPTICALLY ACTIVE CARBONYL COMPOUNDS | BASF SE (DE) | 2017-10-25 | — | — | EP | disclosed |
| EP-2139835-B1 | METHOD FOR SYNTHESIZING OPTICALLY ACTIVE CARBONYL COMPOUNDS | BASF SE (DE) | 2017-05-10 | — | — | EP | disclosed |
| US-20170027172-A1 | USE OF SUBSTITUTE OXO TETRAHYDROQUINOLINE SULFONAMIDES OR SALTS THEREOF FOR RAISING STRESS TOLERANCE OF PLANTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-02-02 | — | — | US | disclosed |
| WO-2017009321-A1 | SUBSTITUTED OXO-TETRAHYDROQUINOLINYL-PHOSPHINIC ACID AND PHOSPHINIC ACID AMIDES OR SALTS THEREOF AND USE THEREOF TO INCREASE STRESS TOLERANCE IN PLANTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-01-19 | — | — | WO | disclosed |
| US-9469662-B2 | Process for preparing optically active biophosphinylalkanes | BASF SE (DE) | 2016-10-18 | — | — | US | disclosed |
| WO-2016128365-A1 | SUBSTITUTED 1-CYCLOALKYL-2-OXOTETRAHYDROQUINOLIN-6-YL-SULFONAMIDES OR SALTS THEREOF AND USE THEREOF TO INCREASE STRESS TOLERANCE IN PLANTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2016-08-18 | — | — | WO | disclosed |
| EP-2746271-B1 | Phenyl-substituted 1, 3, 5-triazine compounds as intermediates for electroluminescent molecules | TOSOH CORP (JP) | 2016-08-17 | — | — | EP | disclosed |
| WO-2016097242-A1 | METHOD FOR SYNTHESIZING OPTICALLY ACTIVE CARBONYL COMPOUNDS | BASF SE (DE) | 2016-06-23 | — | — | WO | disclosed |
| CN-105647274-A | Compound, ink, ink case and ink injection record method | 佳能株式会社 | 2016-06-08 | — | — | CN | disclosed |
| EP-2746271-A1 | Phenyl-substituted 1, 3, 5-triazine compounds as intermediates for electroluminescent molecules | Tosoh Corporation (JP) | 2014-06-25 | — | — | EP | disclosed |
| EP-2141158-B1 | PHENYL-SUBSTITUTED 1,3,5-TRIAZINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING THE SAME AS COMPONENT | TOSOH CORP (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-8569485-B2 | Phenyl-substituted 1,3,5-triazine compound, process for producing the same, and organic electroluminescent device containing the same as component | TOSOH CORPORATION (JP) | 2013-10-29 | — | — | US | disclosed |
| US-20120313090-A1 | PHENYL-SUBSTITUTED 1,3,5-TRIAZINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING THE SAME AS COMPONENT | SAGAMI CHEMICAL RESEARCH INSTITUTE (JP) | 2012-12-13 | — | — | US | disclosed |
| EP-1930329-B1 | 1,3,5-TRIAZINE DERIVATIVE, METHOD FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING SAME AS COMPONENT | TOSOH CORP (JP) | 2012-10-24 | — | — | EP | disclosed |
| US-8268997-B2 | Phenyl-substituted 1,3,5-triazine compound, process for producing the same, and organic electroluminescent device containing the same as component | TOSOH CORPORATION (JP) | 2012-09-18 | — | — | US | disclosed |
| US-7994316-B2 | 1,3,5-triazine derivative, production method thereof and organic electroluminescence device comprising this as a composing component | TOSOH CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7973198-B2 | Method for synthesizing optically active carbonyl compounds | BASF SE (DE) | 2011-07-05 | — | — | US | disclosed |
| EP-1913007-B1 | PROCESS FOR PREPARING OPTICALLY ACTIVE DIPHOSPHANES | BASF SE (DE) | 2011-06-22 | — | — | EP | disclosed |
| US-20110053770-A1 | SUBSTITUTED AMINOTHIAZOLES AND THEIR USE AS FUNGICIDES | BAYER CROPSCIENCE AG (DE) | 2011-03-03 | — | — | US | disclosed |
| EP-1802561-B1 | METHOD FOR THE PRODUCTION OF OPTICALLY ACTIVE CARBONYL COMPOUNDS | BASF SE (DE) | 2011-01-12 | — | — | EP | disclosed |
| US-7858642-B2 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20100249406-A1 | PHENYL-SUBSTITUTED 1,3.5-TRIAZINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING THE SAME AS COMPONENT | TOSOH CORPORATION (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100152494-A1 | METHOD FOR SYNTHESIZING OPTICALLY ACTIVE CARBONYL COMPOUNDS | BASF SE (DE) | 2010-06-17 | — | — | US | disclosed |
| EP-2141158-A1 | PHENYL-SUBSTITUTED 1,3,5-TRIAZINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING THE SAME AS COMPONENT | Tosoh Corporation (JP) | 2010-01-06 | — | — | EP | disclosed |
| EP-2139835-A1 | METHOD FOR SYNTHESIZING OPTICALLY ACTIVE CARBONYL COMPOUNDS | BASF SE (DE) | 2010-01-06 | — | — | EP | disclosed |
| US-20090281311-A1 | 1,3,5-TRIAZINE DERIVATIVE, PRODUCTION METHOD THEREOF AND ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING THIS AS A COMPOSING COMPONENT | TOSOH CORPORATION (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090270367-A1 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | disclosed |
| US-7534921-B2 | Method for the production of optically active carbonyl | BASF AKTIENGESELLSCHAFT (DE) | 2009-05-19 | — | — | US | disclosed |
| US-20090042961-A1 | OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. | 2009-02-12 | — | — | US | disclosed |
| WO-2008132057-A1 | METHOD FOR SYNTHESIZING OPTICALLY ACTIVE CARBONYL COMPOUNDS | BASF SE (DE) | 2008-11-06 | — | — | WO | disclosed |
| US-20080269528-A1 | Method for the Production of Optically Active Carbonyl | BASF AKTIENGESELLSCHAFT (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080242893-A1 | Process for Preparing Optically Active Diphosphanes | BASF AKTIENGESELLSCHAFT (DE) | 2008-10-02 | — | — | US | disclosed |
| EP-1930329-A1 | 1,3,5-TRIAZINE DERIVATIVE, METHOD FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING SAME AS COMPONENT | Tosoh Corporation (JP) | 2008-06-11 | — | — | EP | disclosed |
| US-7385085-B2 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| EP-1913007-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE DIPHOSPHANES | BASF SE (DE) | 2008-04-23 | — | — | EP | disclosed |
| EP-1802561-A1 | METHOD FOR THE PRODUCTION OF OPTICALLY ACTIVE CARBONYL COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2007-07-04 | — | — | EP | disclosed |
| US-20070149584-A9 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | JOHN VARGHESE | 2007-06-28 | — | — | US | disclosed |
| EP-1773758-A1 | OXIME DERIVATIVE HYDROXYETHYLAMINE ASPARTYL-PROTEASE INHIBITORS | Elan Pharmaceuticals, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-1773756-A2 | OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | Elan Pharmaceuticals, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2007012655-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE DIPHOSPHANES | BASF SE (DE) | 2007-02-01 | — | — | WO | disclosed |
| EP-1735293-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-12-27 | — | — | EP | disclosed |
| EP-1734942-A1 | SUBSTITUTED UREA AND CARBAMATE, PHENACYL-2-HYDROXY-3-DIAMINOALKANE, AND BENZAMIDE-2-HYDROXY-3-DIAMINOALKANE ASPARTYL-PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-12-27 | — | — | EP | disclosed |
| EP-1729755-A1 | METHODS OF TREATMENT OF AMYLOIDOSIS USING ASPARTYL-PROTEASE INIHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20060135581-A1 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-06-22 | — | — | US | disclosed |
| US-20060128715-A1 | Oxime derivative hydroxyethylamine aspartyl-protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |
| WO-2006040096-A1 | METHOD FOR THE PRODUCTION OF OPTICALLY ACTIVE CARBONYL COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006010094-A1 | OXIME DERIVATIVE HYDROXYETHYLAMINE ASPARTYL-PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| WO-2006010095-A2 | OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20060014790-A1 | Methods of treatment of amyloidosis using spirocyclohexane aspartyl-protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-01-19 | — | — | US | disclosed |
| US-20050261273-A1 | Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-11-24 | — | — | US | disclosed |
| US-20050239790-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| WO-2005087215-A1 | SUBSTITUTED UREA AND CARBAMATE, PHENACYL-2-HYDROXY-3-DIAMINOALKANE, AND BENZAMIDE-2-HYDROXY-3-DIAMINOALKANE ASPARTYL-PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087752-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005070407-A1 | METHODS OF TREATMENT OF AMYLOIDOSIS USING ASPARTYL-PROTEASE INIHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| US-4139537-A | 3-Aryloxy-1-(2- or 4-iminodihydro-1-pyridyl)-2-propanol antiarrhythmic compounds | COOPER LABORATORIES, INC. (US) | 1979-02-13 | — | — | US | disclosed |
| US-4139537-A | 3-Aryloxy-1-(2- or 4-iminodihydro-1-pyridyl)-2-propanol antiarrhythmic compounds | COOPER LABORATORIES, INC. (US) | 1979-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (21 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261273-A1 | Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors | DNPEP, ASPH, PEPD | ESR1 4516/4885SLC6A2 4010/4885TAAR1 2372/4885 |
| US-20060135581-A1 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | ASPH, DNPEP, APP | ESR1 3282/4885SLC6A2 1547/4885TAAR1 1940/4885 |
| US-20050239790-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | DNPEP, MME, ANPEP | ESR1 3735/4885SLC6A2 251/4885TAAR1 1466/4885 |
| US-20180244598-A1 | METHOD FOR SYNTHESIZING OPTICALLY ACTIVE CARBONYL COMPOUNDS | CBR3, CBR1, HRH4 | ESR1 1903/4885SLC6A2 2627/4885TAAR1 958/4885 |
| US-20110053770-A1 | SUBSTITUTED AMINOTHIAZOLES AND THEIR USE AS FUNGICIDES | ABAT, ALDH7A1, TH | ESR1 2109/4885SLC6A2 1708/4885TAAR1 373/4885 |
| US-20090042961-A1 | OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ASPH, DNPEP, APP | ESR1 3282/4885SLC6A2 1547/4885TAAR1 1940/4885 |
| US-20060014790-A1 | Methods of treatment of amyloidosis using spirocyclohexane aspartyl-protease inhibitors | ASPH, DNPEP, ACE | ESR1 4760/4885SLC6A2 2654/4885TAAR1 2256/4885 |
| US-20100249406-A1 | PHENYL-SUBSTITUTED 1,3.5-TRIAZINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING THE SAME AS COMPONENT | H1-5, H1-4, H1-2 | ESR1 598/4885SLC6A2 3096/4885TAAR1 532/4885 |
| US-20180020662-A1 | Substituted 1-cycloalkyl-2-oxotetrahydroquinolin-6-ylsulfonamides or salts thereof and use thereof to increase stress tolerance in plants | CBR3, CBR1, CBS | ESR1 4800/4885SLC6A2 2564/4885TAAR1 1902/4885 |
| US-10301244-B2 | Method for synthesizing optically active carbonyl compounds | CBR3, CBR1, HRH4 | ESR1 1903/4885SLC6A2 2627/4885TAAR1 958/4885 |
| US-20070149584-A9 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | ASPH, DNPEP, APP | ESR1 3282/4885SLC6A2 1547/4885TAAR1 1940/4885 |
| US-20080269528-A1 | Method for the Production of Optically Active Carbonyl | CBR1, CBR3, HMOX1 | ESR1 4044/4885SLC6A2 4730/4885TAAR1 2163/4885 |
| US-20090270367-A1 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | DNPEP, MME, ANPEP | ESR1 3735/4885SLC6A2 251/4885TAAR1 1466/4885 |
| US-20060128715-A1 | Oxime derivative hydroxyethylamine aspartyl-protease inhibitors | ASPH, DNPEP, APP | ESR1 3465/4885SLC6A2 1757/4885TAAR1 1798/4885 |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | DNPEP, MME, ANPEP | ESR1 3735/4885SLC6A2 251/4885TAAR1 1466/4885 |
| US-20100152494-A1 | METHOD FOR SYNTHESIZING OPTICALLY ACTIVE CARBONYL COMPOUNDS | HMOX1, HMOX2, CBR1 | ESR1 3106/4885SLC6A2 4705/4885TAAR1 3988/4885 |
| US-20180199575-A1 | SUBSTITUTED OXOTETRAHYDROQUINOLINYLPHOSPHINIC ACID AND PHOSPHINIC ACID AMIDES OR SALTS THEREOF AND USE THEREOF TO INCREASE STRESS TOLERANCE IN PLANTS | PPA1, PHOSPHO1, PIP4K2C | ESR1 4777/4885SLC6A2 2413/4885TAAR1 2666/4885 |
| US-20090281311-A1 | 1,3,5-TRIAZINE DERIVATIVE, PRODUCTION METHOD THEREOF AND ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING THIS AS A COMPOSING COMPONENT | KCNJ2, KCNA4, KCNJ4 | ESR1 1709/4885SLC6A2 1669/4885TAAR1 117/4885 |
| US-20180057437-A1 | METHOD FOR SYNTHESIZING OPTICALLY ACTIVE CARBONYL COMPOUNDS | CBR3, CBR1, HRH4 | ESR1 1903/4885SLC6A2 2627/4885TAAR1 958/4885 |
| US-20080242893-A1 | Process for Preparing Optically Active Diphosphanes | PHOSPHO1, DCTPP1, DCPS | ESR1 2674/4885SLC6A2 4036/4885TAAR1 4020/4885 |
| US-20170027172-A1 | USE OF SUBSTITUTE OXO TETRAHYDROQUINOLINE SULFONAMIDES OR SALTS THEREOF FOR RAISING STRESS TOLERANCE OF PLANTS | TST, GSS, SQOR | ESR1 4219/4885SLC6A2 846/4885TAAR1 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.